Replies to post #17977 on COSCIENS Biopharma Inc (CSCI)

[longboarder7892]

The placement shares are so underwater they are going to keep dumping those shares now that the time restrictions are off its been 6 months since the placement . Cut in half no hedge fund wants to hold on any longer now that they can sell them .
February 16, 2021 6,896,552 common shares of Aeterna, at a price to the public of $1.45 per share

[longboarder7892]

I hope this doesnt happen again it could happen just count the days-- But thats when I bought this pos last time when it was .30 will it happen again probably
NASDAQ notifications

On January 8, 2020, the Company announced that it had received a notification letter from NASDAQ indicating that, because the closing bid price of the Company’s common stock for 30 consecutive business days was below $1.00 per share, the Company no longer meets the minimum bid price requirement set forth in NASDAQ Listing Rule5550(a)(2). NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

[longboarder7892]

I hope this doesnt happen again to AEZS it could happen just count the days-- how many days has it been under $1.00? But thats when I bought this pos last time when it was .30 will it happen again probably Just count the days.
NASDAQ notifications

On January 8, 2020, the Company announced that it had received a notification letter from NASDAQ indicating that, because the closing bid price of the Company’s common stock for 30 consecutive business days was below $1.00 per share, the Company no longer meets the minimum bid price requirement set forth in NASDAQ Listing Rule5550(a)(2). NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

[longboarder7892]

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance;
July 29 2021 - 08:05AM

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that on July 28, 2021, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the “Rule”).